Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q5T1H1: Variant p.Ser2211Leu

Protein eyes shut homolog
Gene: EYS
Feedback?
Variant information Variant position: help 2211 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Serine (S) to Leucine (L) at position 2211 (S2211L, p.Ser2211Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In RP25; uncertain significance. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 2211 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 3165 The length of the canonical sequence.
Location on the sequence: help SNGNNCGKQFLHLFLVEGRP S VKYGCGNSQNILTVSANYSI The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         SNGNNC-GKQFLHLFLVEGRPSVKYGCGNSQNILT-----VSANYSI

Zebrafish                     CREQDL-GERFLHVFLQNARAVARLGCGAAH-ILT-----A

Drosophila                    AAAQGTKGGHYMALFLQKGLMQFQFSCGLQTMLLSELETPV

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 22 – 3165 Protein eyes shut homolog
Domain 2145 – 2339 Laminin G-like 2
Alternative sequence 595 – 3165 Missing. In isoform 2 and isoform 3.



Literature citations
Mutation spectrum of EYS in Spanish patients with autosomal recessive retinitis pigmentosa.
Barragan I.; Borrego S.; Pieras J.I.; Gonzalez-del Pozo M.; Santoyo J.; Ayuso C.; Baiget M.; Millan J.M.; Mena M.; El-Aziz M.M.; Audo I.; Zeitz C.; Littink K.W.; Dopazo J.; Bhattacharya S.S.; Antinolo G.;
Hum. Mutat. 31:E1772-E1800(2010)
Cited for: VARIANTS RP25 SER-745; ARG-1484; VAL-2017; LEU-2211; LYS-2503 AND GLU-2945; VARIANTS PRO-1987; ASP-2040 AND CYS-2556; EYS is a major gene for rod-cone dystrophies in France.
Audo I.; Sahel J.-A.; Mohand-Saied S.; Lancelot M.-E.; Antonio A.; Moskova-Doumanova V.; Nandrot E.F.; Doumanov J.; Barragan I.; Antinolo G.; Bhattacharya S.S.; Zeitz C.;
Hum. Mutat. 31:E1406-E1435(2010)
Cited for: VARIANTS RP25 SER-618; SER-745; SER-1110; ARG-1176; PHE-1232; TYR-1682; GLY-1747; MET-1869; TYR-2139; PRO-2189; LEU-2211; THR-2829; TYR-2911 AND GLU-2928; VARIANTS GLN-94; ILE-112; MET-120; LEU-135; PHE-136; ASN-326; ASN-532; LEU-551; ARG-571; SER-631; VAL-641; ILE-834; ARG-938; LYS-1163; VAL-1263; GLU-1325; VAL-1361; GLU-1365; SER-1419; THR-1451; TRP-1515; GLY-1517; VAL-1662; ILE-1664; LEU-1739; PHE-1748; SER-1837; VAL-1873; ILE-1902; GLY-1915; PRO-1987; ALA-1993; VAL-1999; ASP-2040; SER-2151; GLN-2326; CYS-2556; ARG-2599; PRO-2757 AND ILE-2831;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.